Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02886065 · ClinicalTrials.gov registry record · Phase 1
A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM
A Phase 1 study of Smoldering Multiple Myeloma, sponsored by Massachusetts General Hospital.
- Active
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
- 6
- Study locations
NCT02886065 is a Phase 1 study of Smoldering Multiple Myeloma that is active but no longer recruiting, run by Massachusetts General Hospital. The registered enrollment target is 19 participants, below the 799-participant average among 20 other Smoldering Multiple Myeloma trials with a reported enrollment target (98% lower). The trial reports 6 study locations across 4 states.
The verdict
NCT02886065, a Phase 1 study of Smoldering Multiple Myeloma, is active but no longer recruiting, sponsored by Massachusetts General Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
- 6
- Study locations
Study Summary
This research study is studying a targeted therapy as a possible treatment for Smoldering Multiple Myeloma. The following intervention will be involved in this study: * Lenalidomide * Citarinostat (CC-96241) * PVX-410
Conditions Studied
Interventions
- DRUG Lenalidomide
- DRUG Hiltonol
- BIOLOGICAL PVX-410
- DRUG Citarinostat
Study Locations (6)
Massachusetts
- Massachusetts General Hospital - Boston
- Beth Israel Deaconess Medical Center - Boston
- Dana-Farber Cancer Institute - Boston
New York
- Weill Cornell Medical College - New York
North Carolina
- Duke University Medical Center - Durham
Ohio
- University Hospital of Cleveland- Seidman Cancer Center - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2017-03-07 |
| Est. Completion | 2026-09-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02886065
The ClinicalTrials.gov registry entry for NCT02886065 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 799-participant average among 20 other Smoldering Multiple Myeloma trials with a reported enrollment target (98% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Smoldering Multiple Myeloma appearing as the primary indexed condition, and to 4 interventions - of which Lenalidomide is the first listed.
NCT02886065 reports 6 study locations spanning 4 distinct geographic areas - top geographies include Massachusetts, New York, North Carolina.
Frequently Asked Questions
What is clinical trial NCT02886065 about?
NCT02886065 is a clinical study titled "A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM". This research study is studying a targeted therapy as a possible treatment for Smoldering Multiple Myeloma. The following intervention will be involved in this study: * Lenalidomide * Citarinostat (CC-96241) * PVX-410
What is the current status of trial NCT02886065?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2017-03-07. Estimated completion is 2026-09-15.
What conditions does trial NCT02886065 study?
This clinical trial studies the following conditions: Smoldering Multiple Myeloma.
What interventions are being tested in trial NCT02886065?
The interventions under investigation include: Lenalidomide (DRUG), Hiltonol (DRUG), PVX-410 (BIOLOGICAL), Citarinostat (DRUG).
Who is sponsoring clinical trial NCT02886065?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02886065 being conducted?
This trial has 6 study locations across Massachusetts, New York, North Carolina, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Smoldering Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Immuno-PRISM (PRecision Intervention Smoldering Myeloma)
RECRUITING · Phase 2
-
Smoldering Myeloma High-Risk Patient Observation and Longitudinal Insight Trial
RECRUITING
-
Screening for AL Amyloidosis in Smoldering Multiple Myeloma
RECRUITING
-
Registry for Adults With Plasma Cell Disorders (PCD's)
RECRUITING
-
Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma
RECRUITING · Phase 2
-
A Study Comparing a Plant-Based Diet With Supplements and Placebo in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM)
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.